February 21, 2024Open Access

A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The tumor-suppressor p53 is commonly inactivated in colorectal cancer and pancreatic ductal adenocarcinoma, but existing treatment options for p53-mutant (p53

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Alruwaili et al. (Wed,) studied this question.

synapsesocial.com/papers/68e7832ab6db6435876f618d https://doi.org/https://doi.org/10.1016/j.xcrm.2024.101434

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Balanced Production of Ribosome Components Is Required for Proper G1/S Transition in Saccharomyces cerevisiae2013 · 49 citations
2DNA replication and mismatch repair safeguard against metabolic imbalances2017 · 10 citations
3Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer2019 · 508 citations
4Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer1998 · 105 citations
5<i>p53</i> mutation is common in microsatellite stable, <i>BRAF</i> mutant colorectal cancers2011 · 48 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo